Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen(University of Helsinki), David Jenkins(GlaxoSmithKline (Belgium)), F. Xavier Bosch(Institut d'Investigació Biomédica de Bellvitge), Paulo Naud(Hospital de Clínicas de Porto Alegre), Jorge Salmerón(Mexican Social Security Institute), Cosette M. Wheeler(University of New Mexico), Song-Nan Chow(National Taiwan University Hospital), Dan Apter(Sexual Health Clinic), Henry C Kitchener(University of Manchester), Xavier Castellsagué(Institut d'Investigació Biomédica de Bellvitge), Newton Sérgio de Carvalho(Hospital de Clínicas Universidade Federal do Paraná), S. Rachel Skinner(The Kids Research Institute Australia), Diane M. Harper(Dartmouth College), James Hedrick(Ohio Pediatric Research Association), Unnop Jaisamrarn(Chulalongkorn University), Genara Limson(Makati Medical Center), Marc Dionne(Centre hospitalier universitaire de Québec), Wim Quint(DDL Diagnostic Laboratory), Bart Spiessens(GlaxoSmithKline (Belgium)), Pascal Peeters(GlaxoSmithKline (Belgium)), Frank Struyf(GlaxoSmithKline (Belgium)), Susan L. Wieting(GlaxoSmithKline (Belgium)), Matti Lehtinen(Tampere University), Gary Dubin(GlaxoSmithKline (United States))
Cited by 1,313
Abstract
Related Papers
No related papers found
Powered by citation graph analysis